Natixis boosted its stake in shares of Aetna Inc (NYSE:AET) by 41.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,235,009 shares of the company’s stock after purchasing an additional 361,170 shares during the quarter. Aetna accounts for approximately 1.2% of Natixis’ holdings, making the stock its 12th biggest position. Natixis owned 0.38% of Aetna worth $226,023,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its position in Aetna by 101.0% in the first quarter. Wells Fargo & Company MN now owns 2,797,748 shares of the company’s stock valued at $472,819,000 after purchasing an additional 1,405,859 shares during the period. Commerzbank Aktiengesellschaft FI raised its position in Aetna by 108.3% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 6,470 shares of the company’s stock valued at $1,093,000 after purchasing an additional 3,364 shares during the period. Mackay Shields LLC purchased a new stake in Aetna in the first quarter valued at approximately $10,782,000. Stephens Inc. AR raised its position in Aetna by 12.5% in the first quarter. Stephens Inc. AR now owns 8,264 shares of the company’s stock valued at $1,397,000 after purchasing an additional 917 shares during the period. Finally, D.A. Davidson & CO. raised its position in Aetna by 47.2% in the first quarter. D.A. Davidson & CO. now owns 8,367 shares of the company’s stock valued at $1,414,000 after purchasing an additional 2,684 shares during the period. Hedge funds and other institutional investors own 83.52% of the company’s stock.
NYSE:AET opened at $202.73 on Friday. The firm has a market capitalization of $66.11 billion, a price-to-earnings ratio of 20.56, a price-to-earnings-growth ratio of 1.73 and a beta of 0.68. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.74 and a quick ratio of 0.74. Aetna Inc has a 52 week low of $149.69 and a 52 week high of $203.47.
Several research firms have commented on AET. Zacks Investment Research downgraded shares of Aetna from a “hold” rating to a “sell” rating in a research note on Tuesday, July 24th. ValuEngine upgraded shares of Aetna from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Credit Suisse Group dropped their price target on shares of Aetna from $208.00 to $194.00 and set a “neutral” rating for the company in a research note on Monday, May 14th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $202.00 price target on shares of Aetna in a research note on Thursday, August 2nd. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Aetna presently has an average rating of “Hold” and an average price target of $200.38.
Aetna Inc operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.
Featured Article: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.